Drew M. Pardoll
Immunologist who helped define the PD-1 pathway's role in cancer and built one of the largest immunotherapy institutes.
Co-discovered PD-L2 and contributed to the clinical development of PD-1 blockade; directs the Bloomberg~Kimmel Institute.
| Title | Journal | Year |
|---|---|---|
| The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer | 2012 |
This small trial explained why colorectal cancer had seemed immune-resistant (most is MMR-proficient) and established the principle that a genomic feature, not the tissue of origin, can predict immunotherapy response. It led directly to the 2017 tissue-agnostic approval of pembrolizumab and to routine MMR/MSI testing of many cancers. Every patient with advanced dMMR cancer should now be considered for checkpoint blockade.
This study is why PD-1 inhibitors were developed across cancers rather than in melanoma alone: unexpected activity in lung cancer, historically thought immune-resistant, changed drug development priorities industry-wide. It also introduced PD-L1 immunohistochemistry as a candidate biomarker and pneumonitis as a signature toxicity. Within five years PD-1 blockade was approved in more than ten cancers.
Tumours hide from T cells by displaying PD-L1; blocking that interaction lets the immune system attack. This is the mechanism of pembrolizumab, nivolumab, atezolizumab and their relatives, which now treat more than 20 cancer types.
Pages like this
not linked directly; found by shared links- PersonSuzanne L. Topalian
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Society for Immunotherapy of Cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1.
- ProductCosibelimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-L1, Immune checkpoint inhibitors.
- PersonDung T. Le
Shares Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1.
- PersonJulie R. Brahmer
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, PD-1.
- PersonF. Stephen Hodi
Shares Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer, Society for Immunotherapy of Cancer, PD-1, Immune checkpoint inhibitors.
- PairingCaution: checkpoint inhibitors in first-line ovarian cancer
Shares PD-L1, PD-1, Immune checkpoint inhibitors.
- ProductPenpulimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors.
- ProductRetifanlimab
Shares PD-1 / PD-L1 immune checkpoint & T-cell activation, PD-1, Immune checkpoint inhibitors.